Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 1(2)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00141232Phase 4Completed

Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Role: collaborator

NCT02249429Phase 2Completed

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Role: collaborator

NCT02483858Phase 1Completed

Study of Oral PQR309 in Patients With Advanced Solid Tumors

Role: collaborator

NCT02723877Phase 1Completed

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Role: collaborator

All 4 trials loaded